Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (91-100 of 158) with videos related to

Pageof 16
Sort By:
Haematologica|June 21, 2011
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinibMassimo Breccia, Roberto Latagliata, Fabio Stagno, et al.
Annals of Hematology|April 20, 2023
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trialsLuigia Luciano, Roberto Latagliata, Gabriele Gugliotta, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 13, 2013
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24Fabio Efficace, Michele Baccarani, Massimo Breccia, et al.
Haematologica|October 8, 2008
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upFrancesca Palandri, Fausto Castagnetti, Nicoletta Testoni, et al.
Blood|August 21, 2004
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani, Giovanni Martinelli, Gianantonio Rosti, et al.
Targeted Oncology|October 18, 2021
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management ToolsFausto Castagnetti, Gianni Binotto, Isabella Capodanno, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Leukemia|September 4, 2019
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapyFabio Efficace, Fabio Stagno, Alessandra Iurlo, et al.
Leukemia|December 2, 2020
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGSSimona Soverini, Margherita Martelli, Luana Bavaro, et al.
Pageof 16

Showing results (91-100 of 158) with videos related to

Sort By:
Pageof 16
Haematologica|June 21, 2011
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinibMassimo Breccia, Roberto Latagliata, Fabio Stagno, et al.
Annals of Hematology|April 20, 2023
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trialsLuigia Luciano, Roberto Latagliata, Gabriele Gugliotta, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 13, 2013
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24Fabio Efficace, Michele Baccarani, Massimo Breccia, et al.
Haematologica|October 8, 2008
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upFrancesca Palandri, Fausto Castagnetti, Nicoletta Testoni, et al.
Blood|August 21, 2004
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani, Giovanni Martinelli, Gianantonio Rosti, et al.
Targeted Oncology|October 18, 2021
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management ToolsFausto Castagnetti, Gianni Binotto, Isabella Capodanno, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Leukemia|September 4, 2019
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapyFabio Efficace, Fabio Stagno, Alessandra Iurlo, et al.
Leukemia|December 2, 2020
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGSSimona Soverini, Margherita Martelli, Luana Bavaro, et al.
Pageof 16